Study protocol of a randomised, double-blind, placebo-controlled, two-arm parallel-group, multi-centre phase 3 pivotal trial to investigate the efficacy and safety of recombinant human alkaline phosphatase for treatment of patients with sepsis-associated acute kidney injury
-
Pickkers, Peter (Nijmegen)
;
Angus, Derek C (University of Pittsburgh School of Medicine) ;
Arend, Jacques (AM-Pharma BV) ;
Bellomo, Rinaldo (Austin Hospital) ;
van den Berg, Erik (AM-Pharma BV) ;
Bernholz, Juliane (AM-Pharma BV) ;
Bestle, Morten (Copenhagen) ;
Broglio, Kristine (Berry Consultants) ;
Carlsen, Jan (AM-Pharma BV) ;
Doig, Christopher J ;
Ferrer, Ricard (Universitat Autònoma de Barcelona. Departament d'Infermeria) ;
Joannidis, Michael (Medical University Innsbruck) ;
Francois, Bruno (University of Limoges) ;
Doi, Kent (The University of Tokyo Hospital) ;
Kellum, John A ;
Laterre, Pierre-François (Brussels) ;
Liu, Kathleen (University of California San Fransisco) ;
Mehta, Ravindra L (University of California) ;
Murray, Patrick T (Dublin) ;
Ostermann, Marlies (King's College London) ;
Pettilä, Ville (Helsinki) ;
Richards, Sharon (PHASTAR) ;
Young, Paul (Wellington) ;
Zarbock, Alexander (Universität Münster) ;
Kjølbye, Anne Louise (AM-Pharma BV)
visitant ::
identificació
Subscriure's to this discussion. You will then receive all new comments by email.
